Trial
NCT03373305
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
—
Condition
CD30-Positive Neoplastic Cells Present
Intervention
Brentuximab Vedotin
Why stopped
contract not executed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-30